Covid-19 investment from anti-vaccine Novak Djokovic

Novak Djokovic, who returned from the gate of Australia, where he went for a record due to his anti-vaccination, is on the agenda this time with his investment.

It turned out that the famous tennis player, who was not accepted to the country he went to for the Australian Open on the grounds that he threatened public health, has a biotechnology company working on the COVID-19 drug.

Ivan Loncarevic, CEO of Denmark-based company QuantBioRes, announced that Djokovic bought 80 percent of the company in the summer of 2020.

The drug, which aims to prevent the damage caused by the Corona virus to human cells, is planned to be tested in clinical tests in Britain this summer.

The cost of Djokovic’s investment, which has earned more than $150 million in revenue throughout his career, has not been disclosed.

The world number 1, who could not participate in the Australian Open because his visa was revoked, missed his chance to win the 21st Grand Slam title, breaking Federer and Nadal’s record.